Fig. 1From: Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms JAK2 V617F allele frequencies as measured by next-generation sequencing. Samples included 18 negative controls (NC) and 3 samples of patient 31, namely buccal swab (BS) and peripheral blood (PB) samples in July 2014, and peripheral blood sample in October 2014.Back to article page